Nuevas formas de vehiculización de agentes hipotensores para el tratamiento del glaucoma

  1. Andres Guerrero, Vanessa
Zuzendaria:
  1. María del Rocío Herrero Vanrell Zuzendaria
  2. Irene Teresa Molina Martínez Zuzendaria

Defentsa unibertsitatea: Universidad Complutense de Madrid

Fecha de defensa: 2011(e)ko ekaina-(a)k 29

Epaimahaia:
  1. Julián García Feijoo Presidentea
  2. Beatriz de las Heras Polo Idazkaria
  3. Virginia Merino Sanjuán Kidea
  4. Nicolas Tsapis Kidea
  5. Carmen Álvarez Lorenzo Kidea
Saila:
  1. Farmacia Galénica y Tecnología Alimentaria

Mota: Tesia

Teseo: 113230 DIALNET

Laburpena

Glaucoma is the second leading cause of blin dness in the world. It is a chronic optic neuropathy which can lead to complete loss of vision if an adequate treatment is not used in time. At the moment there is no cure for glaucoma and the available treatments are chronic and only manage to contr ol or decrease the evolution of the pathology. These types of treatments, consisting of the instillation of eye drops once or twice per day, are usually associated to short- and long-term adverse effects that compromise the patient compliance...